Mavacamten · Camzyos
Small molecule
Evidence outlook
Approved: Hypertrophic Cardiomyopathy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Heart Failure · Phase 2 · investigational in the US
Also approved (3)
- Treatment of symptomatic obstructive hypertrophic cardiomyopathy
- Treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults (Camzyos; MAH Bristol-Myers Squibb Pharma EEIG)
- CAMZYOS (mavacamten capsules) is indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) Class II-III in adult patients.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
EXPLORER-HCM NCT03470545 · Obstructive Hypertrophic Cardiomyopathy EXPLORER-HCM was a randomized, double-blind, placebo-controlled Phase 3 trial in 251 adults with symptomatic obstructive hypertrophic cardiomyopathy. The primary endpoint was a composite clinical response built from peak oxygen consumption and NYHA class at week 30: 37% with mavacamten vs 17% with placebo (difference 19.4%, 95% CI 8.7 to 30.1, p=0.0005), so the primary was met. Source: the peer-reviewed paper (Olivotto et al., Lancet 2020). Registry: NCT03470545 | 3 | Percentage of Participants Achieving A Clinical Response (30 weeks) 2020-03-14 | Clinical response at week 30 (pVO2 and NYHA composite): mavacamten 45/123 (37%) vs placebo 22/128 (17%), difference +19.4% (95% CI 8.7 to 30.1), p=0.0005 (Olivotto et al., Lancet 2020). | Partial signal | link ↗ |
View 3 more trials
ODYSSEY-HCM NCT05582395 · Cardiomyopathy, Hypertrophic The trial was randomized, double-blind, placebo-controlled, and included 580 participants, with clinical symptom/function and exercise-capacity primary endpoints. Both primary comparisons favored mavacamten numerically but missed statistical significance: KCCQ-23 CSS (p=0.056) and peak VO2 (p=0.066), supporting moderate rather than strong evidence. Registry: NCT05582395 | 3 | Change From Baseline in KCCQ-23 CSS at Week 48 (From First dose to week 48); Change From Baseline in pVO2 at Week 48 (From First dose to week 48) 2025-03-06 | Stopped early (terminated). Key figures are not recorded here. | Partial signal | link ↗ |
VALOR-HCM NCT04349072 · HOCM, Hypertrophic Obstructive Cardiomyopathy In this randomized, quadruple-blind, placebo-controlled trial, 56 participants received mavacamten and 56 received placebo. The hard clinical primary endpoint—a week-16 composite of the decision to undergo septal reduction therapy or continued guideline eligibility—was met in favor of mavacamten, occurring in 10 participants versus 43 with placebo (p<0.0001). Registry: NCT04349072 | 3 | Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 2022-02-07 | Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 (Week 16): Mavacamten 10 Participants | Placebo to Mavacamten 43 Participants | Reliable signal | link ↗ |
NCT06253221 NCT06253221 · Hypertrophic Cardiomyopathy Registry: NCT06253221 | 3 | Change from baseline in Valsalva left ventricular outflow tract (LVOT) (VLVOT) gradient (At Week 28) 2025-11-25 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (4)
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (4)
What this study did
What this study did
What this study did
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Early phase / not applicable (1)
What this study did
Competitive landscape
Other Cardiac myosin (inhibitor) drugs
Aficamten, HRS-1893, Delocamten, Ulacamten. Compare all 5 Cardiac myosin (inhibitor) drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Heart Failure: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Mavacamten (Camzyos): this drug | Phase 2 | Small molecule | Cardiac myosin (inhibitor) | Weak signal | Featured results are safety only in this race | |
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | Reliable signal | NCT04564742: Primary hierarchical composite outcome (win ratio analysis, DAPA-MI): win ratio 1.34 (95% CI 1.20-1.50), P<0.001, favoring dapagliflozin over placebo; n=4017 (2019 dapagliflozin vs 1998 placebo) NCT03619213: Primary composite outcome (worsening heart failure or cardiovascular death): dapagliflozin 16.4% vs placebo 19.5%; hazard ratio 0.82 (95% CI 0.73-0.92, p<0.001) | |
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | Reliable signal | NCT03057951: Primary composite endpoint (CV death or HF hospitalization) event rate: 13.8% (empagliflozin) vs 17.1% (placebo); HR 0.79, 95% CI 0.69-0.90; 21% relative risk reduction. NCT03057977: Primary composite outcome (cardiovascular death or hospitalization for worsening heart failure) at median 16 months: 19.4% (361/1863) with empagliflozin vs 24.7% (462/1867) with placebo; hazard ratio 0.75 (95% CI 0.65-0.86), P<0.001 | |
| Ferric Carboxymaltose (Injectafer / Ferinject) | Approved | Iron Complex (iv) | Iron repletion | Partial signal | NCT03037931: Primary endpoint, hierarchical composite of death and heart failure hospitalization at 12 months and change in 6-minute walk distance at 6 months (significance level 0.01): unmatched win ratio 1.10 (99% CI 0.99 to 1.23), Wilcoxon-Mann-Whitney P=0.02. Components, ferric carboxymaltose vs placebo: deaths 131 (8.6%) vs 158 (10.3%); heart failure hospitalizations 297 vs 332; 6-minute walk change +8 vs +4 m. missed | |
| Finerenone (Kerendia) | Approved | Small molecule | Mineralocorticoid receptor | Reliable signal | NCT04435626: Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events (From randomization up until the end of study, with an average study duration of 32 months): Finerenone (BAY94-8862) 1083 events | Placebo 1283 events | |
| Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX) | Approved | Small molecule | NKCC2 | Weak signal | Featured results are non-efficacy only in this race | |
| Furosemide (subcutaneous, SQ Innovation) (Lasix ONYU) | Approved | Small molecule | NKCC2 | not yet graded | No reviewed efficacy summary in this indication | |
| Isosorbide Dinitrate / Hydralazine (BiDil) | Approved | Small molecule | Hydralazine/isosorbide dinitrate (fixed combination) | Partial signal | NCT00047775: Primary composite score (all-cause mortality, first heart-failure hospitalization, quality of life) favoured isosorbide dinitrate/hydralazine vs placebo (p=0.021); the trial stopped early for a 43% reduction in all-cause mortality (p=0.012) (BiDil label, A-HeFT). | |
| Ivabradine (Corlanor) | ApprovedUS marketing discontinued | Small molecule | If (funny) channel | Reliable signal | NCT02441218: Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure. (All over the study (up to 42 months).): Ivabradine 793 participants | Placebo 937 participants | |
| Sacubitril / Valsartan (Entresto) | Approved | Small molecule | Neprilysin + Angiotensin II receptor (dual) | Partial signal | NCT01035255: Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization (up to 51 months): LCZ696 — Primary Composite: 914 participants; CV death: 558 participants; 1st HF Hospitalization: 537 participants | Enalapril — Primary Composite: 1117 participants; CV death: 693 participants; 1st HF Hospitalization: 658 participants NCT01920711: Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations. (Total follow up time (up to 57 months)): LCZ696 — Primary Composite Events: 894 Events; Total Hospitalizations for heart failure: 690 Events; Cardiovascular death: 204 Events | Valsartan — Primary Composite Events: 1009 Events; Total Hospitalizations for heart failure: 797 Events; Cardiovascular death: 212 Events missed | |
| Sotagliflozin (Inpefa) | Approved | Small molecule | SGLT1/2 (dual) | Partial signal | NCT03315143: Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF) (Up to 30 months): Sotagliflozin 5.6 events per 100-person years | Placebo 7.5 events per 100-person years NCT03521934: Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF) (Up to 21.9 months): Sotagliflozin 51 events per 100-person years | Placebo 76.3 events per 100-person years | |
| Torsemide (Soaanz) | Approved | Small molecule | NKCC2 | not yet graded | No reviewed efficacy summary in this indication | |
| Vericiguat (Verquvo) | Approved | Small molecule | Soluble guanylate cyclase | Partial signal | NCT02861534: CV death or first HF hospitalization, vericiguat vs placebo: 897 of 2526 (35.5%) vs 972 of 2524 (38.5%) over a median 10.8 months; HR 0.90 (95% CI 0.82 to 0.98), P = 0.02. Met. NCT05093933: Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization: Participants With an Event Per 100 Patient-Years (Up to approximately 36 months (from randomization to the primary completion data cutoff)): Vericiguat 11.3 Pts. with event/100 patient-yrs at risk | Placebo 12.2 Pts. with event/100 patient-yrs at risk missed | |
| Alprostadil | Phase 3 | Small molecule | Prostaglandin E1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Balcinrenone | Phase 3 | Small molecule | Mineralocorticoid receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Baxdrostat (Baxfendy) | Phase 3 | Small molecule | Aldosterone synthase (CYP11B2) | not yet graded | No reviewed efficacy summary in this indication | |
| CardiAMP | Phase 3 | Cell therapy | Cardiac cell therapy | Partial signal | NCT02438306: 3-tiered Finkelstein-Schoenfeld primary endpoint at 12 months (interim, 102 of eventual 125 patients): Tier 1 all-cause death 5.6% CardiAMP vs 5.3% control (P=.42); Tier 2 MACCE 16.7% vs 15.8% (P=.82); Tier 3 6MWT change +36.1m vs +33.4m (P=.6) - none reached significance; DSMB futility review concluded the trial was unlikely to meet its primary endpoint missed | |
| Coramitug | Phase 3 | Monoclonal antibody | Transthyretin (TTR) | not yet graded | No reviewed efficacy summary in this indication | |
| Elecoglipron | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Ferric Derisomaltose (Monoferric / Monofer) | Phase 3 | Iron Complex (iv) | Iron repletion | Weak signal | NCT00537186: Single-arm, open-label safety study with no comparator and no formal efficacy test. All registered primary outcomes are safety measures (adverse events, serious adverse events, physical examination, vital signs, laboratory tests). A published pilot study that appears to be this trial (Hildebrandt et al. 2010, n=20) reported no treatment-related adverse reactions and no clinically significant changes in laboratory safety tests or vital signs over 8 weeks. | |
| HiCM-188 (allogeneic iPSC-Cardiomyocytes) | Phase 3 | Cell therapy | Cardiac cell therapy | Partial signal | No reviewed efficacy summary in this indication | |
| Icodextrin (peritoneal Ultrafiltration) (Extraneal) | Phase 3 | Glucose Polymer Solution (peritoneal Dialysis) | Peritoneal ultrafiltration | Weak signal | NCT00368641: All-cause Hospitalization (Unadjusted) (6 to 24 months): Intervention Group 5.33 hospitalizations per year (95% CI 3.13 to 9.05) vs Standard Therapy 1.69 hospitalizations per year (95% CI 0.95 to 2.99) | |
| Levosimendan (Simdax) | Phase 3 | Small molecule | Cardiac troponin C (calcium sensitizer) | Partial signal | NCT00348504: All-cause mortality at 180 days occurred in 173 (26%) patients in the levosimendan group and 185 (28%) patients in the dobutamine group (hazard ratio, 0.91; 95% confidence interval, 0.74-1.13; P = .40). missed NCT00048425: REVIVE II, n=600: 5-day clinical-course composite primary endpoint improved 33% more often and worsened 26% less often with levosimendan vs placebo (p=0.015). | |
| Maridebart Cafraglutide (MariTide) | Phase 3 | Peptide | GLP-1R agonist; GIPR antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Omecamtiv Mecarbil | Phase 3 | Small molecule | Cardiac myosin (activator) | Reliable signal | NCT02929329: Time to Cardiovascular Death or First Heart Failure Event (From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.): Omecamtiv Mecarbil 37% vs Placebo 39.1% NCT03759392: Change in Peak Oxygen Uptake on Cardiopulmonary Exercise Testing From Baseline to Week 20 (Baseline and Week 20): Omecamtiv Mecarbil -0.239 mL/min/kg (Standard Error 0.1718) vs Placebo 0.207 mL/min/kg (Standard Error 0.2412) missed | |
| OPC-61815 (Samtasu) | Phase 3 | Small molecule | Vasopressin V2 receptor | Partial signal | NCT03772041: Change From Baseline in Body Weight (Baseline, Day 6): OPC-61815 Injection 16 mg -1.67 kg (95% CI -1.93 to -1.41) vs Tolvaptan Tablet 15mg -1.36 kg (95% CI -1.62 to -1.1) | |
| QiShenYiQi | Phase 3 | Botanical | Traditional Chinese medicine (multi-component) | Partial signal | No reviewed efficacy summary in this indication | |
| Recombinant Human Neuregulin-1 (rhNRG-1) (Neucardin) | Phase 3 | Protein / enzyme therapeutic | ErbB2/ErbB4 (neuregulin pathway) | Partial signal | No reviewed efficacy summary in this indication | |
| Rexlemestrocel-L | Phase 3 | Cell therapy | Mesenchymal precursor cells (MPCs) | Weak signal | Featured results are safety only in this race | |
| Sotatercept (Winrevair) | Phase 3 | Protein / enzyme therapeutic | Activin receptor type IIA (ActRIIA) | not yet graded | No reviewed efficacy summary in this indication | |
| Tolvaptan (Samsca) | Phase 3 | Small molecule | Vasopressin V2 receptor | Partial signal | NCT00071331: All-cause mortality: tolvaptan 25.9% vs placebo 26.3% (HR 0.98, 95% CI 0.87-1.11, P=.68). Composite of CV death or HF hospitalization: tolvaptan 42.0% vs placebo 40.2% (HR 1.04, 95% CI 0.95-1.14, P=.55). missed | |
| Vicadrostat | Phase 3 | Small molecule | Aldosterone synthase (CYP11B2) | not yet graded | No reviewed efficacy summary in this indication | |
| Danicamtiv | Phase 2/3 | Small molecule | Cardiac myosin (activator) | Weak signal | NCT03447990: Troponin I increase: 3/12 danicamtiv vs 0/12 placebo in SAD cohorts; 7/30 danicamtiv vs 0/10 placebo in MAD cohorts. | |
| Istaroxime | Phase 2/3 | Small molecule | Na-K ATPase / SERCA2a | Partial signal | NCT02617446: Change in E/Ea Ratio (24 hours): Istaroxime 0.5 µg/kg/Min -4.55 Unitless ratio (95% CI -6.05--3.04) vs Placebo Cohort I -1.55 Unitless ratio (95% CI -3.77-0.67) vs Istaroxime 1.0 µg/kg/Min -3.16 Unitless ratio (95% CI -4.09--2.24) vs Placebo Cohort II -1.08 Unitless ratio (95% CI -2.30-0.13); p=0.029 (Istaroxime 0.5 µg/kg/Min vs Placebo Cohort I), p=0.009 (Istaroxime 1.0 µg/kg/Min vs Placebo Cohort II) | |
| AC01 | Phase 2 | Small molecule | Ghrelin receptor | Weak signal | No reviewed efficacy summary in this indication | |
| ADR-002K | Phase 2 | Cell therapy | Cardiac cell therapy | not yet graded | No reviewed efficacy summary in this indication | |
| Bucindolol (Gencaro) | Phase 2 | Small molecule | Beta-1/beta-2 adrenergic receptor (genotype-guided) | Partial signal | NCT01970501: Time to First Event of Symptomatic Atrial Fibrillation/Atrial Flutter (AF/AFL) or All Cause Mortality (ACM) During the 24-week Follow-up Period After Establishment of Stable Sinus Rhythm (SR) on Study Drug [End of Treatment Week 24]. (end of treatment week 24): Bucindolol Hydrochloride 35.9 days (IQR 9 to 53) vs Metoprolol Succinate 33.2 days (IQR 6 to 47) missed | |
| CDR132L | Phase 2 | RNA / oligonucleotide | microRNA-132 | Weak signal | Featured results are safety only in this race | |
| Corteria COR-1167 | Phase 2 | Peptide | Corticotropin-releasing factor receptor 2 | not yet graded | No reviewed efficacy summary in this indication | |
| Delocamten | Phase 2 | Small molecule | Cardiac myosin (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| Deramiocel | Phase 2 | Cell therapy | Cardiac cell therapy | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-9057 | Phase 2 | Small molecule | Vasopressin V1a/V2 receptor (dual) | Weak signal | No reviewed efficacy summary in this indication | |
| HU6 | Phase 2 | Small molecule | Mitochondrial uncoupling | Partial signal | NCT05284617: Weight change at 3 months (450 mg HU6 dose): -6.8 lb from baseline (p<0.0001); -6.3 lb vs placebo (p=0.003) | |
| Jia Shen Tablet | Phase 2 | Botanical | Multi-target (ginsenoside) | Weak signal | No reviewed efficacy summary in this indication | |
| JK07 | Phase 2 | Biologic (subtype unspecified) | HER3 × ErbB4 | Weak signal | Featured results are safety only in this race | |
| JTT-861 | Phase 2 | Small molecule | Pyruvate dehydrogenase | Partial signal | No reviewed efficacy summary in this indication | |
| Ninerafaxstat (IMB-101) | Phase 2 | Small molecule | Cardiac fatty-acid oxidation | Weak signal | NCT04826159: Primary, resting cardiac PCr/ATP change from baseline (single arm, no comparator): Part 1 (type 2 diabetes and obesity) +0.39 (95% CI 0.16 to 0.62; P=0.002); Part 2 (with HFpEF) +0.15 (95% CI 0.03 to 0.26; P=0.02). Dobutamine-stress PCr/ATP (Part 1) is not reported in the abstract. | |
| Pexerelgon | Phase 2 | Small molecule | Relaxin receptor (RXFP1) / relaxin | Partial signal | No reviewed efficacy summary in this indication | |
| PF-07328948 | Phase 2 | Small molecule | Branched-chain ketoacid dehydrogenase kinase (BDK) | not yet graded | No reviewed efficacy summary in this indication | |
| R2R01 | Phase 2 | Peptide | Relaxin receptor (RXFP1) / relaxin | Weak signal | No reviewed efficacy summary in this indication | |
| Ribupatide | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Safiglipron (HRS-7535) | Phase 2 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Tovinontrine | Phase 2 | Small molecule | PDE9 | Partial signal | No reviewed efficacy summary in this indication | |
| Ulacamten | Phase 2(overall) | Small molecule | Cardiac myosin (inhibitor) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Umiposgene Parvec (AB-1002) | Phase 2 | Gene therapy / editing | Protein inhibitor-1 (gene therapy) | Weak signal | NCT04179643: Phase 1 first-in-human trial of a single antegrade coronary infusion of AB-1002 in NYHA III non-ischemic heart failure: no adverse events or serious adverse events were attributed by the investigators to the study treatment. Mean left ventricular ejection fraction rose from 30.5% at baseline to 42.2% at 12 months in cohort 1 and from 24.5% to 36.7% in cohort 2, and all patients with baseline and 12-month assessments had an improvement in ejection fraction of at least 5%. | |
| XTR003 | Phase 2 | Diagnostic (pet Tracer) | Myocardial fatty-acid metabolism (PET imaging) | not yet graded | No reviewed efficacy summary in this indication | |
| AAV1.SERCA2a | Phase 1/2 | Gene therapy / editing | SERCA2a (gene therapy) | not yet graded | No reviewed efficacy summary in this indication | |
| HS-001 | Phase 1/2 | Cell therapy | Cardiac cell therapy | not yet graded | No reviewed efficacy summary in this indication | |
| HS235 | Phase 1/2 | Peptide | Activin receptor type IIA (ActRIIA) | not yet graded | No reviewed efficacy summary in this indication | |
| HucMSC Intramyocardial Therapy | Phase 1/2 | Cell therapy | Cardiac cell therapy | not yet graded | No reviewed efficacy summary in this indication | |
| PolyCore | Phase 1/2 | Solution | Peritoneal ultrafiltration | not yet graded | No reviewed efficacy summary in this indication | |
| Anhui HygeianCells EE001 | Phase 1 | Biologic (subtype unspecified) | Cardiac cell therapy | Weak signal | No reviewed efficacy summary in this indication | |
| HJB647 | Phase 1 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 62 furthest-along competitors are listed; 13 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Camzyos (Mavacamten) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
What to watch
2028 (2)
October 2028 (1)
What to watch
December 2028 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent